CRISPR Therapeutics CRSP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$122.93M+9.6% | -$130.61M-250% | -$106.44M-23.9% | -$208.55M-65.0% | -$136M-16.6% | ||
| $4.32M-8.8% | $5.66M+16.9% | $4.43M-6.5% | $4.65M-4.0% | $4.74M-2.0% | ||
| $16.32M-19.2% | $18.08M-17.6% | $16.6M-22.9% | $17.61M-25.6% | $20.21M+4.2% | ||
| -$0+100% | —— | —— | —— | -$25M+87.5% | ||
| -$13.02M-130% | $4.42M+156% | $12.18M+132% | —— | $43M+355% | ||
| $247K-61.0% | -$3.85M-2,089% | -$212K— | $93K+104% | $634K+121% | ||
| -$199K+98.1% | $13.55M+35.7% | —— | —— | -$10.54M-2,340% | ||
| -$8.8M-291% | $8.31M-45.1% | $10.14M+47.0% | $7.33M-10.4% | -$2.25M-127% | ||
| -$427K+48.2% | —— | -$834K-55.6% | -$892K-229% | -$824K-63.5% | ||
| -$108.9M-102% | -$92.55M-85.0% | -$84.63M+20.8% | -$113.88M-19.1% | -$53.95M-149% | ||
| $504K+145% | $517K+104% | $74K-66.2% | $117K-83.5% | $206K-71.4% | ||
| —— | $175.5K— | $175.5K— | $175.5K— | $175.5K— | ||
| $4.62M-7.7% | —— | —— | $4.7M-12.7% | $5M-33.3% | ||
| -$410.74M-1,979% | —— | -$119.23M+26.2% | $69.98M+155% | -$19.76M+79.8% | ||
| -$722K-108% | $111.49M+645% | $278.11M+4,533% | $0— | $8.52M-97.0% | ||
| $13.53M— | —— | —— | —— | $0— | ||
| $591.91M+5,490% | $116.41M+590% | $296.77M+2,978% | $2.26M— | $10.59M-96.5% | ||
| -$32K-178% | $1K+101% | —— | $80K— | $41K+473% | ||
| $72.24M+215% | $61.06M— | $92.88M+136% | -$41.57M— | -$63.07M-120% | ||
| —— | —— | —— | —— | —— | ||
| -$1.52M-32.1% | -$1.34M-30.8% | -$1.45M+4.0% | -$1.27M-39.9% | -$1.15M-19.2% | ||
| $247K-61.0% | -$3.85M-2,089% | -$212K— | $93K+104% | $634K+121% | ||
| -$8.8M-291% | $8.31M-45.1% | $10.14M+47.0% | $7.33M-10.4% | -$2.25M-127% | ||
| $4.62M-7.7% | —— | —— | $4.7M-12.7% | $5M-33.3% | ||
| —— | $175.5K— | $175.5K— | $175.5K— | $175.5K— | ||
| $13.53M— | —— | —— | —— | $0— | ||
| $6.16M+197% | $4.92M+157% | $18.66M+413% | $2.28M+318% | $2.07M-91.8% | ||
| -$32K-178% | $1K+101% | —— | $80K— | $41K+473% | ||
| $4.14M+28.6% | —— | $2.78M— | $680K— | $3.22M-28.8% | ||
| $1.12M— | —— | —— | —— | $0— | ||
| $600M— | —— | —— | —— | $0— | ||
| -$109.4M-102% | -$93.07M-85.1% | -$84.71M+20.9% | -$114M-18.4% | -$54.15M-150% | ||
| -$109.4M-102% | -$93.07M-85.1% | -$84.71M+20.9% | -$114M-18.4% | -$54.15M-150% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CRISPR Therapeutics generate?
- CRISPR Therapeutics (CRSP) generated -$400.0M in operating cash flow over the trailing twelve months.
- What is CRISPR Therapeutics's free cash flow?
- After $1.2M of capital expenditures, CRISPR Therapeutics's free cash flow was -$401.2M over the trailing twelve months, down 30.3% year over year.
- Where does CRISPR Therapeutics's cash flow data come from?
- Every line is extracted from CRISPR Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
